CarThera® designs and develops innovative medical devices using the therapeutic potential of ultrasound to significantly improve the efficacy, comfort, and cost of treating a range of medical conditions.
CarThera® has focused on the treatment of brain tumors for the first applications of its innovative medical devices. CarThera’s devices are developed by a multidisciplinary team of medical doctors, biologists, and physicists. This multidisciplinary effort takes into account, from the early stages of development, the needs of both patients and physicians, and leads to innovative solutions.
The medical devices developed by CarThera originate from the work of Dr. Alexandre Carpentier, a neurosurgeon at the University Hospital Pitié-Salpêtrière in Paris, France. They are designed to respond to unmet clinical needs.
The two medical devices currently in development are designed to be used during outpatient procedures for the thermal ablation of brain tumors (SonoProbe) and for improving the efficacy of chemotherapy (SonoCloud®).
Both devices are innovative at multiple levels:
Biologically — They employ the use of new tissue-ultrasound interactions.
Clinically — They use interventional MRI procedures for the brain.
Technologically — They use advanced technology for miniaturization.
Organizationally — They open the possibility of new methods of outpatient care.
Pr Carpentier Interview / Autrement Editions – may 2011.
« A new vision of surgery »
“I have always been interested in the development of new surgical technologies. Even though current surgical techniques provide an immense benefit to patients, I’m convinced that we can do even better, with the development of techniques that decrease both invasiveness and expense. My medical objective is a bit idealistic: I envision surgery as a convergence of medical expertise, advanced materials, physical principles, and computational power. Such a convergence will allow for treatments with better efficacy and security, with diminished morbidity, under local anaesthesia, and on an outpatient basis. It may appear unfeasible, but we are on the way to success: We now have proof of concept and efficacy in pre-clinical studies for our two technologies under development.”